NAD+ (1,000 mg vial) dosage protocol

1. Draw 3 mL of bacteriostatic water with a sterile syringe.
2. Inject it slowly down the inside wall of the vial, not onto the powder, to avoid foaming.
3. Swirl or roll the vial gently until the powder dissolves. Do not shake it.
4. Label it with the date and the volume of water, and refrigerate at 2-8 °C (36-46 °F), away from light.

• Reconstitute: add 3 mL of bacteriostatic water for a 333 mg/mL solution.
• Amounts in the chart: 50 mg-100 mg each time, by subcutaneous injection, once a day.
• Easy measuring: at 333 mg/mL, one unit (0.01 mL) on a U-100 insulin syringe holds about 3.33 mg.
• Storage: freeze-dried, keep it sealed, cold and away from light (frozen for long storage). Once mixed, refrigerate at 2-8 °C and avoid freezing and thawing.

NAD+ is a coenzyme found in every cell and used in energy metabolism; it is not a peptide, but it is sold alongside them, often as an injection or IV drip. Almost all human trials use oral precursors (NR or NMN) rather than NAD+ itself, and injectable NAD+ is not FDA-approved.

• Primary calculation: 1,000 mg made up to 3 mL equals 333 mg/mL.
• Amounts shown: 50 mg-100 mg per administration. Reported in the research community. It has not been tested as a schedule in human trials.
• Route and frequency: subcutaneous injection, once a day.
• Evidence ceiling: 7 of the 8 studies with a dose in our library were done in people.
• Regulatory status: Not FDA-approved as an injectable drug.

A 1,000 mg vial holds 1,000,000 mcg of NAD+. Adding 3 mL gives 333 mg/mL, so one U-100 unit (0.01 mL) holds 3.33 mg. To get the units for an amount, divide it by 3.33 mg. The units are a volume mark on the syringe, not a measure of potency.

• 50 mg: 0.15 mL, or 15 U-100 units.
• 75 mg: 0.23 mL, or 22.5 U-100 units.
• 100 mg: 0.3 mL, or 30 U-100 units.

Vial coverage by mass: 20 full amounts of 50 mg, 13 full amounts of 75 mg, 10 full amounts of 100 mg per vial, before any handling loss.

If a different volume of water is used, every unit figure changes: recalculate with the calculator above.

NAD+ itself (intravenous)

• Pilot infusion study: 8 healthy men received 750 mg NAD+ over 6 hours (3 received saline). Blood NAD+ did not rise for the first 2 hours, showing infused NAD+ is cleared or broken down fast; no adverse events were seen (Grant 2019).
• Clinic records: in 6 clients given 500 mg IV NAD+ on four days, all reported moderate to severe gut symptoms, faster heart rate or chest pressure during the drip, and infusions took much longer; 8 clients given IV NR had milder symptoms (Reyna 2026).

Precursors taken by mouth (NR and NMN)

• NR in healthy older adults: 1,000 mg a day for 6 weeks was well tolerated and raised NAD+ metabolism (Martens 2018).
• NR in older men's muscle: raised NAD-related molecules in muscle and lowered some inflammatory markers, without changing mitochondrial energy output (Elhassan 2019).
• NR in men with obesity: 12 weeks did not improve insulin sensitivity or body composition (Dollerup 2018).
• NR in Parkinson's disease: raised brain NAD in some patients in a 30-person phase 1 trial, with exploratory signs of benefit (Brakedal 2022).
• NMN in women with prediabetes: 10 weeks increased muscle insulin sensitivity in 13 women compared with placebo (Yoshino 2021).

Verdict: oral precursors reliably raise NAD-related levels and were well tolerated in trials lasting weeks to months, but effects on health outcomes are inconsistent. For injected or infused NAD+, there are no controlled outcome trials, and the little data available point to poor tolerability when given quickly.

Doses used in human studies

• Grant R 2019: 750 mg NAD+ in saline (3 µmol/min) vs saline (dose from the full text) (Intravenous infusion over 6 hours; Single 6-hour infusion, samples up to 8 hours)
• Reyna K 2026: 500 mg NAD+ IV or 500 mg NR IV on four consecutive days (Intravenous infusion; 4 days, with 30 days of follow-up)
• Martens CR 2018: 1,000 mg per day of nicotinamide riboside (from the full text) (Oral; 6 weeks on each arm of a crossover)
• Elhassan YS 2019: 1 g NR per day (Oral; 21 days on each arm of a crossover)
• Dollerup OL 2018: 1000 mg twice daily (Oral; 12 weeks)
• Brakedal B 2022: 1,000 mg NR (Oral; 30 days)
• Yoshino M 2021: 250 mg/day NMN (from the full text) (Oral; 10 weeks)

Every study dose, including animal and cell studies, is in the NAD+ dose table.

For oral NR and NMN, trials of weeks to months reported good tolerability (Dollerup 2018; Gallagher 2026). For IV NAD+, the available reports describe uncomfortable symptoms during infusion, and there are no long-term safety data.

• Infusion reactions: cramping, nausea, vomiting, diarrhoea, faster heart rate and chest pressure were reported with IV NAD+, stopping when the infusion ended (Reyna 2026).
• Product quality: injectable NAD+ from wellness clinics or online sellers is not an FDA-approved drug, so identity, purity and sterility are not checked as they would be for an approved medicine.
• Precursor data do not transfer: safety findings for oral NR or NMN do not show that injected NAD+ is equally tolerated.
• Injection risks: any injected or infused product that is not sterile can cause infection.

• FDA: Not FDA-approved as an injectable drug.
• Evidence limits: reported use is not evidence that a schedule works or is safe. Animal doses do not convert to people, and research products are not made or checked for use in people.
• Status checked on: Oct 26, 2026.